SAN DIEGO, Oct. 06, 2017 (GLOBE NEWSWIRE) -- Arcturus Therapeutics, Inc., a privately held biotechnology company developing novel RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, will provide a corporate overview at the Chardan Gene Therapy Conference, taking place in New York City on Tuesday, October 10, 2017.
Chardan Gene Therapy Conference
| Date: | Tuesday, October 10 |
| Time: | 11:10am Eastern Time |
| Location: | Westin Grand Central New York, Consulate Room |
About the Chardan Gene Therapy Conference Chardan’s Inaugural Gene Therapy Conference will feature nearly 30 companies focusing on exciting technologies in gene therapy, including vector-based gene therapy, small RNA and gene editing. The day will consist of fireside chats, individual company presentations, one-on-one meetings with management and panel discussions focusing on gene therapy pricing and manufacturing. The conference will take place at the Westin Grand Central Hotel in New York.
About Arcturus Therapeutics, Inc. Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies — UNA Oligomer chemistry and LUNAR™ nanoparticle delivery. Arcturus's versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics. The company owns LUNAR nanoparticle delivery and Unlocked Nucleomonomer Agent (UNA) technology including UNA Oligomers, which are covered by its patent portfolio (>110 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus' proprietary UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company's commitment to the development of novel RNA therapeutics has led to partnerships with Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Inc., and Cystic Fibrosis Foundation. For more information, visit www.ArcturusRx.com, the content of which is not incorporated herein by reference. On September 27, 2017, Arcturus and Alcobra Ltd. (Alcobra) (NASDAQ: ADHD ) entered into an agreement and plan of merger and reorganization pursuant to which a wholly-owned subsidiary of Alcobra will merge with and into Arcturus, with Arcturus becoming a wholly-owned subsidiary of Alcobra and the surviving corporation of the merger, and the holders of Arcturus outstanding capital stock immediately prior to the merger will receive ordinary shares representing approximately 60% of the outstanding shares of Alcobra. Upon consummation of the transaction, Alcobra’s name will be changed to Arcturus Therapeutics, Ltd., and Alcobra will change its ticker symbol to ARCT on NASDAQ.
Forward-looking Statements This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the structure, timing and completion of the proposed merger transaction; and the combined company’s listing on NASDAQ after closing of the proposed merger. You should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Except as otherwise required by law, all parties disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Additional Information about the Proposed Merger involving Alcobra and Arcturus and Where to Find It In connection with the previously disclosed proposed merger involving Alcobra and Arcturus, a proxy statement and a proxy card will be furnished to the Securities and Exchange Commission (SEC) and will be mailed to Alcobra’s shareholders seeking any required shareholder approvals in connection with the proposed merger transactions. Before making any voting or investment decision, investors and shareholders are urged to read the proxy statement (including any amendments or supplements thereto) and any other relevant documents that Alcobra may furnish to or file with the SEC when they become available because they will contain important information about the proposed merger transactions.
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
CONTACTS Arcturus Therapeutics 858-900-2660 info@arcturusRx.com
Investors: Andrew McDonald Ph.D. LifeSci Advisors LLC 646-597-6979
